Montpellier company Histalim develops biomarkers to establish tumor immune profiles. In September, Histalim became a subsidiary of the European leader in medical biology, Cerba Healthcare, and now wants to expand internationally.
International developmentIn September, Histalim was acquired by Cerba Healthcare, a European group and international expert in biological diagnostics.
By joining Cerba Healthcare, Histalim becomes part of a network of laboratories with complementary activities, operating in about fifty countries. The company intends to create synergies with the other entities. With its staff of 45 people, Histalim will stay based in the Montpellier Méditerranée Métropole area.
“Developing biomarkers to advance personalized oncology treatments is, by definition, related to medical diagnostics,” notes Jean-Philippe Coton, who continues to retain control over the company.
“The ecosystem here is very strong. It enabled us to find clients beyond our regional borders,” adds the CEO.